How We Work With HCPs
We are committed to ensuring the transparency of our relationships with health care professionals in order to develop innovative medicines, improve health education and better understand patients’ needs. Without our joint efforts, new medicines could never reach the millions of patients who need better treatment options in a range of therapy areas, including cancer, diabetes, depression and Alzheimer’s disease.
During our early scientific research and clinical trial programmes we work with Healthcare Professionals to evaluate the use of medicines in the patient pathway. We recognise the importance of this expertise and time contribution and believe it is appropriate that fees are paid to health care professionals to reimburse them for their efforts.
Once our medicines are approved, we work with physicians to help further translate scientific discoveries into practical, real-world use for patients – creating dialogue to foster better understanding of our medicines so they can make better decisions for their patients. This dialogue is conducted in a range of different ways, including, for example, sponsored speaker programmes and contracted consulting services to provide invaluable insights that help us develop new treatments, better education and ultimately, a better understanding of how we can most significantly help patients along their healthcare journey.
Many healthcare providers prefer to learn about treatment options from their peers and professional colleagues. Expert-led forums facilitate this dialogue and advance our shared goals with physicians of helping to develop a better understanding of medicines so that health care professionals can make better decisions for their patients. This dialogue also provides invaluable insights that help us develop new treatments, educational materials and ultimately gives Lilly a better understanding of how we can most significantly help patients along their health care journey.
We know that it's important these relationships are managed transparently and fully support the European Federation of Pharmaceutical Industries and Association’s (EFPIA’s) commitment to publishing the details of payments and transfers of value made to HCPs and healthcare organisations. This information is published on an individual basis (from 2016) and will be updated annually. These payments are disclosed on a central database; www.disclosureuk.org.uk
INFORMATION FOR HEALTHCARE PROFESSIONALS
If you are a healthcare professional click here for more information
We value your feedback to help us improve the way we do business
Learn more about Lilly's sponsorship policy